The further evolution of biotech
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (1), 75-79
- https://doi.org/10.1038/nrd989
Abstract
Born 20 years ago with the launch of recombinant insulin, the biotechnology industry is maturing, with several leading companies now rivalling traditional pharmaceutical companies in many ways. What might the next 20 years hold for biotech-based drug development?Keywords
This publication has 16 references indexed in Scilit:
- The evolution of biotechNature Reviews Drug Discovery, 2002
- Genome-based pharmacogenetics and the pharmaceutical industryNature Reviews Drug Discovery, 2002
- Proteomics in drug discoveryCurrent Opinion in Chemical Biology, 2002
- The impact of pharmacogenetics and pharmacogenomics on drug discoveryNature Reviews Drug Discovery, 2002
- Identification of a Psoriasis Susceptibility Candidate Gene by Linkage Disequilibrium Mapping with a Localized Single Nucleotide Polymorphism MapGenomics, 2002
- Single-Nucleotide Polymorphism Alleles in the Insulin Receptor Gene Are Associated with Typical MigraineGenomics, 2001
- A 4-Mb High-Density Single Nucleotide Polymorphism-Based Map around Human APOEGenomics, 1998
- The APOE-∊4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and HispanicsJAMA, 1998
- Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer DiseaseJAMA, 1997
- APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASEAnnual Review of Medicine, 1996